Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07228195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SGLT2i Therapy in Islet Transplantation (SIT)

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Jul 15, 2026 to Jul 21, 2026
    • Site details revised
    v5
  2. Start date: May 15, 2026 to Jul 15, 2026v4
  3. Start date: Mar 1, 2026 to May 15, 2026v3
  4. Start date: Dec 1, 2025 to Mar 1, 2026v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Trial Details
NCT Number NCT07228195
Lead Sponsor University of Minnesota
Conditions
(from sponsor)		 Partial Islet Function, TPIAT, Diabetes
Related terms Diabetes Mellitus
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov